Erasca, Inc. (ERAS)
ERASNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$15.37
+0.7162 (+4.89%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $5.46bn
- P/E
- –
- EPS, last 4 quarters
- $-0.4600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.11 to $24.28
- Average volume
- 4.78m
- Previous close
- $14.65
Analysts
8 coveringBuy5 buy, 3 hold, 0 sell
Targets a year out average $24.14, +57.1% from here
Earnings
next estimate $-0.1400Next report Nov 11, 2026
Sep 2025
0.0%
Dec 2025
+9.1%
Mar 2026
+42.1%
Jun 2026
-16.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$34.55m | -$32.60m | -$187.91m | -$47.62m |
| Net income | -$30.61m | -$29.09m | -$183.44m | -$44.08m |
News
8 latest- Tango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung Cancers RTTNews · 5 days ago
- Notable Friday Option Activity: APP, ERAS, CRDOBNK Invest · Sep 25, 2026
- Erasca's Pancreatic Cancer Drug Gains FDA Fast Track Designation RTTNews · Aug 24, 2026
- XBI, APGE, ORKA, ERAS: ETF Outflow AlertBNK Invest · Jul 31, 2026
- Erasca Reaches Analyst Target PriceBNK Invest · Jul 16, 2026
- Erasca Updates Phase 1 Data, Outlines Development Plans For ERAS-0015; Prices $550 Mln Offering RTTNews · Jul 14, 2026
- Tango Therapeutics Rides a New Precision Oncology Trend in 2026Zacks · Jul 2, 2026
- Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?Zacks · Jul 2, 2026
The company
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team's capabilities and experience, further guided by our scientific advisory board which includes the world's leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- erasca.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.